David Dresner
Gastroenterology · New Albany, INNPI 1417955667
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 457 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by AbbVie at 24.7% of the total. Reporting peaked in 2023 at $1,793 and has fallen 96.5% since, to $62 in 2024.
Across 457 payments — averaging $14.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$887
- Johnson & Johnson$839
- Pfizer$301
- Gilead$251
- plus $2K from 32 others
Across 89 payments — averaging $6040.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$382K
- Takeda Pharmaceuticals U.S.A., Inc.$123K
- Pfizer$29K
- Genentech, Inc.$4K
What the payments were for
- Food & beverage$6,527100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 125 | $1,617 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 85 | $1,053 |
| Takeda Pharmaceuticals U.S.A., Inc. | 61 | $887 |
| Johnson & Johnson | 47 | $839 |
| Pfizer | 21 | $301 |
| Gilead | 17 | $251 |
| Sanofi | 8 | $148 |
| Regeneron Healthcare Solutions, Inc. | 6 | $134 |
| Merck | 8 | $120 |
| Daiichi Sankyo Inc. | 7 | $112 |
| Ironwood Pharmaceuticals, Inc | 7 | $112 |
| QOL Medical, LLC | 6 | $99 |
| Ardelyx, Inc. | 5 | $83 |
| Boston Scientific | 4 | $79 |
| Intercept Pharmaceuticals, Inc. | 5 | $77 |
| Alnylam Pharmaceuticals Inc. | 4 | $65 |
| Bristol Myers Squibb | 4 | $64 |
| Evoke Pharma, Inc. | 4 | $53 |
| Organon | 5 | $51 |
| Amgen | 3 | $48 |
| UCB, Inc. | 3 | $37 |
| Tersera Therapeutics LLC | 2 | $29 |
| Pharmacosmos Therapeutics Inc. | 2 | $28 |
| Medtronic(2 entities) | 2 | $28 |
| Celltrion USA Inc. | 1 | $25 |
| CSL Behring | 2 | $25 |
| Redhill Biopharma Inc. | 2 | $23 |
| Mylan Institutional Inc. | 1 | $20 |
| AstraZeneca | 1 | $19 |
| Vivus LLC | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Novo Nordisk | 1 | $14 |
| Fresenius Kabi USA, LLC | 1 | $14 |
| Sandoz | 1 | $13 |
| Romark Laboratories, LC | 1 | $13 |
| Shionogi Inc | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
How this compares
$6,552 in reported general payments places this provider in the 75th percentile of 323 gastroenterology providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 16 | $430,220 |
| CreonLipase/Protease/Amylase | 13 | $44,315 |
| LinzessLinaclotide | 19 | $17,064 |
| Mesalamine | 39 | $14,287 |
| Ursodiol | 14 | $3,476 |
| Dexlansoprazole DrDexlansoprazole | 16 | $2,689 |
| Colestipol Hcl | 27 | $2,485 |
| Pantoprazole Sodium | 152 | $2,482 |
| Budesonide DrBudesonide | 13 | $2,264 |
| Famotidine | 148 | $1,258 |
| Lansoprazole | 12 | $894 |
| Dicyclomine Hcl | 49 | $888 |
| Esomeprazole Magnesium | 29 | $872 |
| Omeprazole | 66 | $788 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 12 | $277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $839 | $430,22016 claims |
| AbbVieCreon, Linzess | $1,617 | $61,37932 claims |
| SandozLansoprazole | $13 | $89412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 323 gastroenterology providers in Indiana.
Other gastroenterology in New Albany
- Jonathan ObertNew Albany$302K
- Robert LuckettNew Albany$61K
- Steven HarrellNew Albany$12K
- Abdul JabbarNew Albany$9K
- Douglas RexIndianapolis$557K
- Ajay JainIndianapolis$432K
- Monika FischerIndianapolis$258K
- Naga ChalasaniIndianapolis$255K
- Matthew BohmWestfield$239K
- Thomas ImperialeIndianapolis$188K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.